Mar 14 |
Larimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial Results
|
Mar 14 |
Larimar Therapeutics GAAP EPS of -$0.30 misses by $0.06
|
Mar 14 |
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
|
Mar 11 |
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
|
Mar 6 |
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
|
Feb 20 |
Over $37M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
|
Feb 16 |
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
|
Feb 15 |
Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
|
Feb 14 |
Larimar Therapeutics rises after pricing $150M stock offering
|
Feb 14 |
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
|